Breast Cancer Clinical Trial

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Summary

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have a Stage IV diagnosis of 1 of the following: Part A: NSCLC (Kirsten rat sarcoma mutant [KRAS mt], PD-L1+); Part B: NSCLC (squamous histology); Part C: metastatic breast cancer (HR+, HER2-); or Part D: locally advanced or metastatic breast cancer (HR+, HER2-)

Part A: must be chemotherapy naïve for metastatic NSCLC
Part B: must have received at least 1 prior therapy containing platinum-based chemotherapy for advanced/metastatic NSCLC
Part C: must have previously received prior treatment with at least 1 but no more than 2 chemotherapy regimens in the metastatic setting
Part D: cannot have received endocrine therapy or chemotherapy as treatment in the locoregionally recurrent or metastatic breast cancer disease setting. Note: Participants may be enrolled if they received prior (neo)adjuvant chemotherapy or endocrine therapy for localized disease.
Are amenable to provide tumor tissue prior to treatment and provide tumor tissue after treatment initiation (both mandatory).
Have presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Have a performance status (PS) ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
Have an estimated life expectancy of ≥12 weeks.
For Part D: Have postmenopausal status due to surgical/natural menopause or chemical ovarian suppression (initiated 28 days prior to Day 1 of Cycle 1) with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or radiation-induced ovarian suppression.

Exclusion Criteria:

Have a personal history of any of the following conditions: syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: subjects with controlled atrial fibrillation for >30 days prior to study treatment are eligible.
Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
Have corrected QT interval of >470 milliseconds on screening electrocardiogram (ECG).
Have history of interstitial lung disease or pneumonitis.
Have history of or active autoimmune disease, or other syndrome that requires systemic steroids or autoimmune agents for the past 2 years.
Have received a live vaccination within 30 days of study start.
Have received prior treatment with an anti PD-1, anti-programmed death ligand 1 (PD-L1), or anti cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.

For Part D Only:

Have initiated bisphosphonates or approved RANK ligand (RANK-L) targeted agents (for example, denosumab) <7 days prior to Cycle 1 Day 1.
Are currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancer. Note: A participant may be enrolled if she received prior (neo)adjuvant endocrine therapy (including, but not limited to anti-estrogens or aromatase inhibitors) for localized disease.
Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer. Note: Participants may be enrolled if they received prior (neo)adjuvant chemotherapy for localized disease.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

100

Study ID:

NCT02779751

Recruitment Status:

Active, not recruiting

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

Highlands Oncology Group
Fayetteville Arkansas, 72703, United States
Univ of California San Francisco
San Francisco California, 94158, United States
University of Colorado School of Medicine
Aurora Colorado, 80045, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven , 3000, Belgium
Centre Hospitalier Universitaire Sart Tilman
Liege , 4000, Belgium
Centre Oscar Lambret
Lille Cedex , 59020, France
CHU de Montpellier-Hopital Arnaud de Villeneuve
Montpellier Cedex 5 , 34295, France
Hopital Larrey
Toulouse , 31059, France
Istituto Scientifico Romagnolo - Studio e la Cura dei Tumori
Meldola Forli, 47014, Italy
IRCCS Ospedale San Raffaele
Milano , 20132, Italy
Nuestra Senora de Sonsoles
Avila , 05004, Spain
Hospital San Pedro de Alcantara
Caceres , 10003, Spain
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain
Hospital Madrid Norte Sanchinarro
Madrid , 28050, Spain
Tri-Service General Hospital
Neihu Taipei , 11490, Taiwan
Taipei Medical University- Shuang Ho Hospital
New Taipei City , 235, Taiwan
Chi-Mei Meical Center, Liouying
Tainan , 73657, Taiwan
National Taiwan University Hospital
Taipei , 10048, Taiwan
Istanbul University Cerrahpasa Medical Faculty
Istanbul , 34098, Turkey
Ege University Faculty of Medicine
Izmir , 35100, Turkey

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

100

Study ID:

NCT02779751

Recruitment Status:

Active, not recruiting

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider